Eli Lilly & Co, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan Seigerman from BMO Capital maintained a Buy rating on the stock and has a $1,100.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Evan Seigerman’s rating is based on several key factors that highlight Eli Lilly & Co’s promising growth prospects. The company’s strategic pricing adjustments for Zepbound vials are expected to enhance patient access, which could drive revenue growth despite the premium pricing compared to competitors like Novo’s Wegovy. This move is part of a broader strategy to expand market share and improve patient affordability, which is crucial in the competitive landscape of diabetes and obesity treatments.
Additionally, Eli Lilly’s pipeline strategy is showing positive results, with recent approvals such as donanemab contributing to the company’s growth trajectory. The anticipated approval of orforglipron, along with the potential of the TRIUMPH-4 data on retatrutide, further strengthens the company’s position in the market. These developments, combined with a robust oncology franchise, support the company’s top-line and bottom-line growth, making it an attractive investment opportunity.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $1,286.00 price target.
Based on the recent corporate insider activity of 152 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.